- Home
- GGAL vs ICLR Comparison
GGAL vs ICLR Comparison
Compare GGAL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | ICLR |
|---|---|---|
| Founded | 1905 | 1990 |
| Country | Argentina | Ireland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.3B |
| IPO Year | 2001 | 2001 |
Fundamental Metrics
Financial Performance| Metric | GGAL | ICLR |
|---|---|---|
| Price | $41.45 | $172.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $69.00 | ★ $178.62 |
| AVG Volume (30 Days) | 764.5K | ★ 805.3K |
| Earning Date | 03-07-2023 | 05-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.29 | N/A |
| Revenue Next Year | $22.88 | N/A |
| P/E Ratio | $13.36 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.89 | $66.57 |
| 52 Week High | $62.11 | $203.91 |
Technical Indicators
Market Signals| Indicator | GGAL | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 31.53 | 57.57 |
| Support Level | $39.90 | $172.65 |
| Resistance Level | $45.01 | $188.49 |
| Average True Range (ATR) | 1.81 | 6.78 |
| MACD | -0.54 | 0.57 |
| Stochastic Oscillator | 7.39 | 73.21 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. The company generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.